IR-News

AUSSENDER



Medigene AG
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 3333 01
E-Mail: investor@medigene.com
pta20220413011
Business news for the stock market

Medigene AG: Medigene participates at upcoming conferences


Planegg/Martinsried (pta011/13.04.2022/07:30) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, will participate at the following upcoming scientific, business development and financial conferences. Medigene's management and/or scientists will be available for one-on-one meetings at these events.

Neoantigen Summit Europe
https://neoantigen-europe.com/
26-28 April 2022

German Biotechnology Days
4-5 May 2022
https://www.biotechnologietage.de/en/

H.C. Wainwright Global Investment Conference
23-25 May 2022
https://hcwevents.com/globalconference/

--- end of press release ---

About Medigene

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Planegg/Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to enhance T cell activity against solid cancers in fields of high unmet medical need.

Medigene's strategy is to develop its own therapies towards clinical proof-of-concept. In addition, the Company offers selected partners the opportunity to discover and develop therapies on the basis of its proprietary technology platforms. In return for such partnerships, Medigene expects to receive upfront and milestone payments as well as research and development funding and royalties on future product sales.

For more information, please visit https://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene

Dr. Anna Niedl
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

LifeSci Advisors

Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)
emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg/Martinsried
Germany
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
e-mail: investor@medigene.com
website: www.medigene.com
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00 (share)
|
|
98.688 Abonnenten
|
200.927 Meldungen
|
83.080 Pressefotos

BUSINESS

04.07.2022 - 14:20 | SRH AlsterResearch AG
04.07.2022 - 13:00 | SRH AlsterResearch AG
04.07.2022 - 11:45 | pressetext.redaktion
04.07.2022 - 10:10 | CNT Management Consulting AG
04.07.2022 - 10:00 | Tools at Work Hard + Soft Vertriebsges.m.b.H.
Top